When Uddhab Gautam received his first dose of vaccine in February, there were fewer cases of Kovid-19 in Nepal.
Now, three months later, coronavirus infection in the Himalayan nation has gone out of control, causing hospital beds and oxygen shortages, and sending most parts of the country into lockdown.
But despite needing it more than ever, the 67-year-old retired banker does not know when he will receive a second dose of AstraZeneca Vaccine Covishield manufactured by the Serum Institute of India (SII).
From his home in Nepal’s capital Kathmandu, he said, “As an older person, I fear contracting the virus.” “I have chosen to stay indoors.”
Gautam’s plight is similar to that shared by millions of people worldwide: as: India’s own coronavirus crisis has increased, Sii – World’s Largest Vaccine Manufacturer – Can no longer export its goods.
Last week, SII said it would not resume delivery to COVAX, a worldwide initiative aimed at distributing vaccines to countries regardless of funding, until its end year.
While the SII decision will be a lifeline for India, which is still reporting around 200,000 new cases a day, the delay is a major problem for developing countries that control their own major outbreaks Are dependent on COVAX.
The world is already 140 million doses lower – and by the end of June, this gap will reach 190 million shots, One of the partners at the United Nations Children’s Agency, COVAX, said last week. UNICEF said that there is currently no time limit to address this shortfall.
This creates a very real problem, not only for countries with limited access to vaccines where cases are exploding, but also for the entire world.
UNICEF Executive Director Henrietta Four said, “We are concerned that the fatal spike in India is a precursor to what would happen if those warnings were not heeded.” said In a news release last week. “The cost for children and families will be incomparable.”
Read full story: